Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum

Clinical Biochemistry

Volumn 43, Issue 18, 2010, Pages 1449-1452

  Patel, Jay L ^a   Erickson, J Alan ^b   Roberts, William L ^a,b   Grenache, David G ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

Carcinoembryonic antigen; CYFRA 21 1; Cytokeratin fragments; Non small cell lung cancer; Squamous cell carcinoma antigen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; ASSAY; AUTOMATION; CANCER PATIENT; CANCER STAGING; CHEMOLUMINESCENCE; ENVIRONMENTAL TEMPERATURE; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SERUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; IMMUNOASSAY; KERATIN-19; LIMIT OF DETECTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 78149501151     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.014     Document Type: Article

References (32)

1. Travis W.D., Colby T.V., Corrin B., Shimosato Y., Brambilla E. WHO International Histological Classification of Tumours 1999, Springer, New York. 3rd ed.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
4. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N Engl J Med 2008, 359:1367-1380.
5. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
6. Kulpa J., Wojcik E., Reinfuss M., Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002, 48:1931-1937.
7. Sawabata N., Maeda H., Yokota S., Takeda S., Koma M., Tokunaga T., et al. Postoperative serum carcinoembryonic antigen levels in patients with pathologic stage IA nonsmall cell lung carcinoma: subnormal levels as an indicator of favorable prognosis. Cancer 2004, 101:803-809.
8. Bonner J.A., Sloan J.A., Rowland K.M., Klee G.G., Kugler J.W., Mailliard J.A., et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 2000, 6:597-601.
9. Molina R., Filella X., Auge J.M., Fuentes R., Bover I., Rifa J., et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003, 24:209-218.
10. Takeuchi S., Nonaka M., Kadokura M., Takaba T. Prognostic significance of serum squamous cell carcinoma antigen in surgically treated lung cancer. Ann Thorac Cardiovasc Surg 2003, 9:98-104.
11. Kao C.H., Hsieh J.F., Ho Y.J., Ding H.J. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. Lung 1999, 177:333-337.
12. Wieskopf B., Demangeat C., Purohit A., Stenger R., Gries P., Kreisman H., et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest 1995, 108:163-169.
13. Dohmoto K., Hojo S., Fujita J., Ueda Y., Bandoh S., Yamaji Y., et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines. Lung Cancer 2000, 30:55-63.
14. Barak V., Goike H., Panaretakis K.W., Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004, 37:529-540.
15. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G., et al. AJCC Cancer Staging Manual 2002, Springer-Verlag, New York. 6th ed.
16. Vollmer R.T., Govindan R., Graziano S.L., Gamble G., Garst J., Kelley M.J., et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003, 9:1728-1733.
17. Nisman B., Biran H., Heching N., Barak V., Ramu N., Nemirovsky I., et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008, 98:77-79.
18. Blankenburg F., Hatz R., Nagel D., Ankerst D., Reinmiedl J., Gruber C., et al. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score. Tumour Biol 2008, 29:272-277.
19. Pujol J.L., Molinier O., Ebert W., Daures J.P., Barlesi F., Buccheri G., et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004, 90:2097-2105.
20. Muley T., Dienemann H., Ebert W. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC. Anticancer Res 2003, 23:4085-4093.
21. Pujol J.L., Boher J.M., Grenier J., Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer 2001, 31:221-231.
22. Ardizzoni A., Cafferata M.A., Tiseo M., Filiberti R., Marroni P., Grossi F., et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006, 107:2842-2849.
23. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res 2008, 14:7813-7821.
24. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135.
25. Moro D., Villemain D., Vuillez J.P., Delord C.A., Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995, 13:169-176.
26. Vassilakopoulos T., Troupis T., Sotiropoulou C., Zacharatos P., Katsaounou P., Parthenis D., et al. Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 2001, 32:137-144.
27. Zhong L.P., Zhu H.G., Zhang C.P., Chen W.T., Zhang Z.Y. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2007, 36:230-234.
28. Uenishi T., Yamazaki O., Yamamoto T., Hirohashi K., Tanaka H., Tanaka S., et al. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21-1) in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006, 13:239-244.
29. Rodriguez C.A., Cruz J.J., Martin T., Gomez A., Olaverri A., Hernandez M. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma. Cancer 2002, 95:670-671. [author reply 671].
30. Nisman B., Barak V., Shapiro A., Golijanin D., Peretz T., Pode D. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002, 94:2914-2922.
31. Nakayama M., Satoh H., Ishikawa H., Fujiwara M., Kamma H., Ohtsuka M., et al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 2003, 123:2001-2006.
32. Nakahama H., Tanaka Y., Fujita Y., Fujii M., Sugita M. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology 1998, 3:207-210.